Mitochondrial Connection: Unraveling the Role of Metabolism and the Brain in Major Human Illnesses

Explore the critical role of mitochondria in metabolism, neuropsychiatric illnesses, encephalopathy, and delirium, with potential therapeutic strategies.

#mitochondria?#mitochondrialdisease?#oxidativestress?#neuroscience?#health?#wellness?#aging?#mentalhealth?#depression?#anxiety?#alzheimers?#ms?#als?#schizophrenia?#bipolardisorder?#metabolism#neuropsychiatry?#nutrition?#metabolicsyndrome?#metabolichealth?#diabetes?#cardiovascularhealth?#diet?#sleepmedicine

Intro

Metabolism plays a crucial role in human health, encompassing the processes responsible for fueling and maintaining the body's biological machinery (thereby: how we grow, defend ourselves, adapt to the environment, self-repair, self-replicate, and self-regulate).

One key player in these processes is the mitochondria, which are often overlooked when considering the root causes of major human illnesses -- and yet are the lynchpin in innate immunity, inflammation, and metabolism (Riley J, et al, 2020). We will explore the connection between mitochondria and various diseases, highlighting their significance in the biological processes that impact our health.

The Fundamentals of Metabolism and Mitochondria

Metabolism is a set of processes that involve the breakdown of nutrients to produce energy (catabolism) and the synthesis of molecules needed for growth, repair, and reproduction (anabolism) (Alberts et al., 2002). The mitochondria, often referred to as the "powerhouses" of the cell, play a central role in metabolism by generating most of the cell's energy supply in the form of adenosine triphosphate (ATP) through a process called oxidative phosphorylation (Wang & Green, 2012).

Mitochondria are involved in energy production and various other cellular processes. As Picard et al. (2015) have mentioned, mitochondria play a crucial role in the immune system, particularly in the context of?innate immunity. Furthermore, they are implicated in?inflammation?(defense),?autophagy?(self-pruning, self-regulation, growth, and proper development), and?apoptosis?(programmed cell death) – processes that contribute to the overall maintenance and regulation of cellular and systems-wide health in the organism. As such, the proper functioning of mitochondria is essential for maintaining overall health and well-being.

Human Mitochondrial Mosaicism: Focus on Metabolic and Neuropsychiatric Illnesses

Mitochondria are essential for cellular energy production and (as we will go into more detail below) play a central role in metabolism, the neuroendocrine-immune landscape, and the gut microbiome. Nevertheless, let us talk about our mitochondrial load as a whole organism. Human mitochondrial mosaicism refers to the presence of genetically distinct populations of mitochondria within an individual, which can arise from mutations in the mitochondrial DNA (mtDNA). This phenomenon can significantly affect health and disease, particularly in metabolic, cardiovascular, and neuropsychiatric illnesses. It can also help explain why some individuals have illnesses to various degrees of expression. In contrast, others with the same or similar level of environmental insult may not have any symptoms or signs of disease.

The extent and distribution of mitochondrial mosaicism can vary significantly among individuals.

Mitochondrial Mosaicism: An Overview

Mitochondrial mosaicism occurs when an individual has a regular and mutant mtDNA mixture within their cells (Rossignol et al., 2003). This mixture can arise from spontaneous mutations during mtDNA replication, errors in mtDNA repair, or the inheritance of mutated mtDNA from the mother (Taylor & Turnbull, 2005). Mutated mtDNA can have varying consequences on mitochondrial function and overall health, depending on the specific mutation and the proportion of affected mitochondria in each cell (Stewart & Chinnery, 2015). The extent and distribution of mitochondrial mosaicism can vary significantly among individuals and this variation in mosaicism can have different effects depending on the organ system in question.

Mitochondrial Mosaicism in Metabolic Disorders

Mitochondrial mosaicism has been implicated in developing various metabolic disorders, including mitochondrial diseases like diabetes. For example, the presence of mutated mtDNA can lead to impaired oxidative phosphorylation, reduced ATP production, and increased production of reactive oxygen species, which can contribute to the development of metabolic diseases such as mitochondrial myopathies and encephalomyopathies (Schon et al., 2012).

Studies have shown that individuals with a higher proportion of mutated mtDNA in their muscle cells exhibit reduced insulin sensitivity and impaired glucose metabolism, which can contribute to the development of diabetes (Maassen et al., 2004). In addition, mitochondrial mosaicism has been associated with an?increased riskof developing type 2 diabetes mellitus. Furthermore, some research suggests that specific mtDNA mutations may also increase the risk of diabetic complications, such as?neuropathy?and?nephropathy?(Rebelo et al., 2011).

Mitochondrial Mosaicism in Neuropsychiatric Disorders

Emerging evidence suggests that mitochondrial mosaicism may also play a role in developing neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, and autism spectrum disorders. Studies have identified the presence of?mutated mtDNA?in the brains of individuals with Alzheimer's and Parkinson's,?which may contribute to the observed mitochondrial dysfunction and neurodegeneration?in these conditions (Coskun et al., 2012; Grünewald et al., 2016).

In the context of autism spectrum disorders, recent research has shown that?children with autism exhibit a higher degree of mtDNA heteroplasmy, or the coexistence of multiple mtDNA genotypes, than their unaffected siblings (Giulivi et al., 2010). This heteroplasmy suggests that mitochondrial mosaicism may contribute to the development of autism, although further research is needed to elucidate the precise mechanisms involved.

Mitochondrial mosaicism represents a complex and multifaceted phenomenon with significant implications for human health and disease. By deepening our understanding of the role of mosaicism in metabolic and neuropsychiatric disorders, we can pave the way for the development of novel, targeted, and personalized interventions that hold the potential to improve patient outcomes and promote overall well-being.

Understanding the complex relationship between mitochondrial mosaicism and human health and disease is an ongoing challenge for researchers. As we continue to unravel the intricacies of this relationship, we must consider the many factors that contribute to the development of metabolic and neuropsychiatric disorders. This includes the presence of mutated mtDNA, the interactions between nuclear and mitochondrial genomes, the gut microbiome's influence on mitochondrial function, and the potential impact of environmental factors.

Future research should focus on identifying specific mtDNA mutations associated with disease risk and understanding the factors that influence the distribution and severity of mosaicism within an individual. Additionally, understanding the role of mitochondrial mosaicism in health and disease may provide new insights into developing preventative strategies and early interventions for at-risk individuals. By deepening our understanding of these mechanisms, we can develop novel, targeted, and personalized interventions that hold the potential to improve patient outcomes and promote overall well-being.

The Neuroendocrine-Immune Landscape and Mitochondria

The impact of mitochondria on neuropsychiatric diseases is becoming increasingly evident as researchers uncover links between mitochondrial dysfunction and various disorders. For example, multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system (CNS). Research has demonstrated that mitochondrial dysfunction and impaired energy metabolism may contribute to the pathogenesis of MS (Witte et al., 2014).

See my other articles on?the Psycho-Neuro-Endocrine-Immune Links in PTSD

Anxiety disorders are another group of conditions in which mitochondrial dysfunction has been implicated. Studies have found that individuals with anxiety disorders may have alterations in mitochondrial function, which could contribute to the development of the disease (Picard et al., 2015).

Neuropathy, a condition characterized by damage to the peripheral nervous system, has also been linked to mitochondrial dysfunction. A study conducted by Melli et al. (2008) showed that impaired mitochondrial function could play a significant role in the development of neuropathy.

Stroke, a leading cause of disability and death worldwide, is another condition in which mitochondria have been implicated. Research has demonstrated that mitochondrial dysfunction can contribute to neuronal death following a stroke, exacerbating the severity of the condition (Sims & Muyderman, 2010).

Similarly, in epilepsy – a neurological disorder characterized by recurrent seizures – mitochondrial dysfunction has been shown to play a role in the pathophysiology of the disease (Kann et al., 2011).

Alzheimer's Disease, a progressive neurodegenerative disorder, is also linked to mitochondrial dysfunction. Studies have shown that mitochondrial dysfunction may contribute to the accumulation of toxic proteins, which can lead to neuronal death and cognitive decline in patients with Alzheimer's disease (Swerdlow et al., 2010).

Likewise, depression and the prototypical psychotic disorder, schizophrenia – two more 'traditional' psychiatric disorders – have been associated with alterations in mitochondrial function. Research has found that individuals with these conditions may have impaired mitochondrial energy metabolism, which could contribute to the development and progression of the diseases (Gardner et al., 2003; Manji et al., 2012).

As previously mentioned, mitochondrial dysfunction has been incriminated in numerous diseases, including neurodegenerative disorders like Alzheimer's disease and Parkinson's disease (Lin & Beal, 2006). Furthermore, as mentioned above, mitochondrial dysfunction correlates to psychiatric disorders such as bipolar disorder and schizophrenia (Manji et al., 2012). The role of mitochondria in these diseases can be attributed to several factors, including impaired energy metabolism, increased oxidative stress, and altered calcium homeostasis (Wang et al., 2014).

For instance, in multiple sclerosis (MS), mitochondrial dysfunction contributes to neurodegeneration by promoting oxidative stress and energy failure in affected neurons (Witte et al., 2014).

In Alzheimer's disease, mitochondrial dysfunction is thought to be involved in the formation of amyloid-beta plaques and neurofibrillary tangles, two hallmark features of the disease (Swerdlow et al., 2014).

Psychosis and Mitochondria

Emerging evidence also suggests a role for mitochondrial dysfunction in the pathophysiology of psychosis. A recent review by F?cking et al. (2020) highlights the role of mitochondrial dysfunction in schizophrenia, the severe psychiatric disorder characterized by hallucinations, delusions, and cognitive deficits. The authors propose that abnormalities in mitochondrial function may contribute to the development of schizophrenia by impairing neuronal connectivity and plasticity, which are essential for normal brain function. As if these interactions were not complex enough, we must also take into account the research demonstrating varying effects (beneficial and toxic) on mitochondrial function by antipsychotic drugs (Cikánková T, et al., 2019, and Susatia F, et al., 2009, and Contreras-Shannon V, et al., 2013, and Vucicevic L, et al., 2014).

Benefits and Drawbacks of a Systems Biology Perspective

The systems biology approach, which focuses on the interplay between neuroanatomy, neuroimmune function, and neuroendocrine function, offers several benefits in understanding the role of mitochondria in neuropsychiatric disorders. One key advantage is identifying common mechanisms and pathways underlying multiple disorders, offering potential therapeutic targets applicable across various conditions (Hood et al., 2004).

For example, research into the role of mitochondrial dysfunction in both Alzheimer's Disease and Parkinson's disease has led to the identification of shared pathways, such as oxidative stress and impaired energy metabolism, that can be targeted for therapeutic intervention (Lin & Beal, 2006). Furthermore, understanding the role of the gut microbiome in modulating mitochondrial function provides another avenue for potential treatments that could benefit multiple neuropsychiatric disorders (Cryan & Dinan, 2012).

However, there are also potential drawbacks to the systems biology perspective. One concern is that the complex interplay between multiple systems can make pinpointing specific causative factors and developing targeted interventions challenging. Additionally, the inherent variability between individuals, such as genetic differences, environmental exposures, and lifestyle factors, can further complicate the identification of common mechanisms and treatment approaches (Hood & Friend, 2011).

Mitochondria play a central role in metabolism, the neuroendocrine-immune landscape, and the gut microbiome, making them a common denominator in developing various major human illnesses. The interconnectedness of these systems provides both opportunities and challenges for understanding the underlying mechanisms of neuropsychiatric disorders and developing targeted interventions.

Further research into the role of mitochondria in human health and disease will be essential for developing novel treatment strategies. This research should focus on the interconnectedness of metabolism, the neuroendocrine-immune landscape, and the gut microbiome and explore the potential for mitochondrial-targeted therapies, gut microbiome modulation, and personalized medicine approaches. Considering the complex interplay between these systems, we may unlock new therapeutic approaches that improve patient outcomes and overall well-being.

Despite the challenges associated with the systems biology perspective, this approach offers valuable insights to help us better understand human health and disease complexities. By embracing the interconnectedness of metabolism, the neuroendocrine-immune landscape, and the gut microbiome, we can unravel the intricate mechanisms underlying the development of neuropsychiatric disorders and other chronic conditions. Ultimately, this understanding will be essential for developing novel, targeted, personalized interventions to improve patient outcomes and promote overall well-being.

As we continue to deepen our understanding of the role of mitochondria in human health, it is crucial to recognize that individual differences will play a significant role in determining the most effective treatment approaches for each person. Personalized medicine, which involves tailoring treatments based on an individual's unique genetic makeup, environmental exposures, and lifestyle factors, is a promising avenue for addressing these individual differences and improving patient outcomes (Hood & Friend, 2011).

Furthermore, recognizing the importance of the gut microbiome in modulating mitochondrial function and overall health highlights the potential benefits of exploring interventions that target the gut microbiome. Such interventions may include dietary modifications, prebiotics, probiotics, and fecal microbiota transplantation, all of which have shown promise in improving various aspects of health, including mental health (Cryan & Dinan, 2012).

The central role of mitochondria in metabolism, position them as a common denominator in the development of numerous major human illnesses.

The central role of mitochondria in metabolism, their role and links within the neuroendocrine-immune landscape, and their associations to the gut microbiome-brain axis (see below) position them as a common denominator in the development of numerous major human illnesses. By adopting a systems biology approach, we can appreciate the complex interplay between these systems and work towards a more comprehensive understanding of the mechanisms underlying neuropsychiatric disorders and other chronic conditions. This knowledge will be invaluable in developing novel, targeted, and personalized interventions that can improve patient outcomes and promote overall well-being.

The Gut, Microbiome, and Mitochondria

The intricate relationship between the gut, the microbiome, and mitochondria has become an area of intense research in recent years. The gut microbiome is a complex community of microorganisms that inhabit the gastrointestinal tract, playing a vital role in various aspects of human health, including metabolism, immune function, and mental health (Cryan & Dinan, 2012).

Research has shown that the gut microbiome can influence mitochondrial function and biogenesis. For example, a study by Saint-Georges-Chaumet et al. (2016) demonstrated that certain gut bacteria can produce short-chain fatty acids (SCFAs) that enhance mitochondrial function and energy metabolism. Moreover, some gut bacteria can modulate the host's immune response by regulating the production of reactive oxygen species (ROS) and mitochondrial-derived peptides, which play essential roles in inflammation and tissue repair (Ryan et al., 2020).

The relationship between the gut microbiome, the immune system, and mitochondria also has implications for neuropsychiatric disorders. Dysbiosis, an imbalance in the gut microbiome, has been linked to various neurological and psychiatric conditions, including autism, anxiety, depression, and schizophrenia (Dinan & Cryan, 2017). Although the underlying mechanisms are not yet fully understood, it is thought that alterations in the gut microbiome may lead to changes in mitochondrial function, which in turn affect the neuroendocrine-immune landscape and contribute to the development of these disorders.

See my other article on?the Gut-Microbiome-Brain link

Mitochondrial Dysfunction and Its Role in Encephalopathy and Delirium

Mitochondrial dysfunction has been increasingly recognized as contributing to developing encephalopathy and delirium. Encephalopathy is characterized by altered mental status, including cognitive impairment, memory loss, and confusion, while delirium is an acute and fluctuating disturbance in attention and awareness (Maldonado, 2018). Both conditions can have severe implications for patients, leading to increased morbidity and mortality (Ely et al., 2004).

One proposed mechanism linking mitochondrial dysfunction to encephalopathy and delirium is through the disruption of neuronal energy metabolism. Mitochondria are essential for producing adenosine triphosphate (ATP), the primary energy source for cellular processes (Wallace et al., 2010). In the brain, neurons depend on a steady supply of ATP to maintain normal function. As such, any impairment in mitochondrial energy production can have detrimental effects on neuronal function and may result in the development of encephalopathy and delirium (Perry et al., 2011).

Several studies have found evidence of mitochondrial dysfunction in patients with encephalopathy and delirium. For example, a study by Perry et al. (2011) reported that patients with septic encephalopathy exhibited impaired mitochondrial function and reduced ATP levels in brain tissue. Similarly, a study by Trzepacz et al. (2017) demonstrated that mitochondrial DNA copy numbers were significantly lower in patients with delirium than in controls, suggesting reduced mitochondrial biogenesis and function in these individuals.

Furthermore, inflammation and oxidative stress have been implicated in the pathophysiology of encephalopathy and delirium, which are known to impact mitochondrial function (Cunningham et al., 2018). Inflammatory cytokines can directly impair mitochondrial respiration and ATP production, while oxidative stress can cause damage to mitochondrial DNA, proteins, and lipids, leading to further dysfunction (Swerdlow, 2011).

In addition to these mechanisms, mitochondrial dysfunction may also contribute to the development of encephalopathy and delirium through its effects on neurotransmitter systems. For instance, the decreased mitochondrial function has been linked to impaired synthesis and release of neurotransmitters, such as dopamine and serotonin, which are crucial for maintaining normal cognitive function (Klinedinst & Regenold, 2015).

Together, these findings highlight the potential role of mitochondrial dysfunction in the pathogenesis of encephalopathy and delirium. As such, therapeutic strategies targeting mitochondrial function may hold promise for preventing and treating these conditions.

As our understanding of the complex interplay between metabolism, the brain, and human illness continues to grow, the role of mitochondria as a common denominator in various diseases becomes increasingly clear. To develop more effective treatments for a wide range of neuropsychiatric and neurological disorders, future research should focus on the central role of mitochondria in metabolism, the neuroendocrine-immune landscape, and the gut microbiome.

One potential avenue for future research is the development of mitochondrial-targeted therapies that aim to improve mitochondrial function and energy metabolism. These therapies could include antioxidants, which have shown promise in reducing oxidative stress and improving mitochondrial function in various neurological conditions (Gardner et al., 2003). Additionally, interventions aimed at modulating the gut microbiome, such as probiotics, prebiotics, and dietary interventions, could improve mitochondrial function by altering the production of short-chain fatty acids and other microbial metabolites (Cryan & Dinan, 2012).

Furthermore, developing personalized medicine approaches considering individual differences in mitochondrial function and gut microbiome composition could lead to more effective and targeted treatments for neuropsychiatric disorders. By tailoring treatments to an individual's unique metabolic and microbial profile, it may be possible to improve patient outcomes and reduce the trial-and-error process often associated with psychiatric treatment.

In conclusion, understanding the central role of mitochondria in metabolism, the neuroendocrine-immune landscape, and the gut microbiome is crucial for developing novel treatment strategies for neuropsychiatric and neurological disorders. By focusing on the interconnectedness of these systems, we can unlock new therapeutic approaches that lead to improved patient outcomes and overall well-being.

By impairing neuronal energy metabolism, disrupting neurotransmitter systems, and promoting inflammation and oxidative stress, mitochondrial dysfunction can lead to the cognitive and attentional disturbances.

Mitochondrial dysfunction is important in developing encephalopathy and delirium. By impairing neuronal energy metabolism, disrupting neurotransmitter systems, and promoting inflammation and oxidative stress, mitochondrial dysfunction can lead to the cognitive and attentional disturbances characteristic of these conditions. Future research should continue to elucidate the mechanisms underlying the relationship between mitochondrial dysfunction, encephalopathy, and delirium, aiming to identify novel therapeutic targets for preventing and treating these debilitating conditions.

As we continue to investigate the relationship between mitochondrial dysfunction, encephalopathy, and delirium, it becomes apparent that much is still to be understood. However, the available evidence points to the significant role of impaired mitochondrial function in the pathophysiology of these conditions. Further research in this area holds promise for developing novel therapeutic strategies. Targeting mitochondrial function may involve strategies to improve energy metabolism, reduce oxidative stress, and attenuate inflammation. For example, using antioxidants and anti-inflammatory agents may help mitigate the damage caused by oxidative stress and inflammation. At the same time, interventions designed to promote mitochondrial biogenesis and function could enhance neuronal energy metabolism (Wallace et al., 2010). Medications used in diabetes management may also hold key insights (Weng G., et al., 2019).

Moreover, understanding the complex interplay between mitochondrial dysfunction, neurotransmitter systems, and other cellular processes may lead to identifying novel drug targets and developing more effective treatments for encephalopathy and delirium. This, in turn, could significantly improve patient outcomes and reduce the burden of these conditions on healthcare systems worldwide. The role of mitochondrial dysfunction in developing encephalopathy and delirium cannot be overstated. As researchers continue to unravel the complex mechanisms underlying these conditions, we can anticipate the development of novel therapeutic strategies targeting mitochondrial function, with the potential to improve patient outcomes and promote overall well-being.

The Example of the Callus: Adaptive Response to the Environment

The concept of adaptive response can be exemplified by the formation of a callus on one's finger, which, although not aesthetically pleasing, is a protective mechanism against environmental stressors. This response is similar to the body's complex, interconnected processes, including metabolism, immune function, and the neuroendocrine-immune landscape. These processes, driven by mitochondria, are designed to protect and repair the body when faced with adverse environmental factors, such as toxins, pathogens, or physical stress.

The adaptive response is a crucial aspect of human health, and its dysregulation can lead to various chronic diseases, including neuropsychiatric disorders (Berk et al., 2013). For instance, adverse childhood experiences (ACEs) can alter the neuroendocrine-immune landscape, leading to increased vulnerability to psychiatric and neurological disorders later in life (Shonkoff et al., 2012). The role of mitochondria in these adaptive responses is essential to understanding the mechanisms underlying the development of these disorders and the potential for targeted interventions.

Future Directions and Potential Therapeutic Implications

Understanding the role of mitochondrial mosaicism in health and disease has potential implications for developing novel therapeutic strategies. For example, interventions aimed at improving mitochondrial function, such as using antioxidants, mitochondrial-targeted agents, or gene therapy, may hold promise for treating metabolic and neuropsychiatric disorders associated with mitochondrial mosaicism (Wallace et al.,2010). Additionally, identifying individuals with a high degree of mitochondrial mosaicism may facilitate the development of personalized treatment approaches that target the specific mtDNA mutations present in each individual.

As our understanding of the complex interplay between metabolism, the brain, and human illness continues to grow, the role of mitochondria as a common denominator in various diseases becomes increasingly clear. To develop more effective treatments for a wide range of neuropsychiatric and neurological disorders, future research should focus on the central role of mitochondria in metabolism, the neuroendocrine-immune landscape, and the gut microbiome.

One potential avenue for future research is the development of mitochondrial-targeted therapies that aim to improve mitochondrial function and energy metabolism. These therapies could include antioxidants, which have shown promise in reducing oxidative stress and improving mitochondrial function in various neurological conditions (Gardner et al., 2003). Additionally, interventions aimed at modulating the gut microbiome, such as probioticsPrebiotics, and dietary interventions, could improve mitochondrial function by altering the production of short-chain fatty acids and other microbial metabolites (Cryan & Dinan, 2012). Furthermore, developing personalized medicine approaches that consider individual differences in mitochondrial function and gut microbiome composition could lead to more effective and targeted treatments for neuropsychiatric disorders. By tailoring treatments to an individual's unique metabolic and microbial profile, it may be possible to improve patient outcomes and reduce the trial-and-error process often associated with psychiatric treatment. As mitochondrial research grows, scientists, clinicians, and patients must remain open to discoveries and innovative treatment approaches. The future of medicine lies in our ability to harness the interconnectedness of our biological systems and develop strategies that address the root causes of disease rather than simply managing symptoms. By embracing the complexity of human health, we can move towards a more holistic, personalized, and effective approach to healthcare that ultimately improves the lives of individuals suffering from a wide range of illnesses.

The relationship between metabolism, mitochondria, neuropsychiatry, and mental health is becoming increasingly apparent as more research is conducted. The complex interplay between mitochondrial function, energy metabolism, and the various processes involved in these neuroendocrine-immune networks highlights the central role of mitochondria in developing and progressing disease processes. This growing body of evidence also underscores the importance of understanding the role of mitochondria in developing effective prevention and treatment strategies for these conditions --not just in increasing our understanding of how our existing treatments work by seemingly intervening beneficially in these roles. It is also essential to further elucidate how mosaicism contributes to developing metabolic, cardiovascular, and neuropsychiatric disorders. This will involve identifying specific mtDNA mutations associated with disease risk and a deeper understanding of the factors that influence the distribution and severity of mosaicism within an individual. Moreover, developing novel therapeutic strategies will require a better understanding of the interactions between nuclear and mitochondrial genomes and the potential impact of the gut microbiome on mitochondrial function and metabolism as a whole. As research on the role of mitochondria in human health continues to evolve, it is becoming increasingly clear that these intra-cellular organelles are involved in a wide range of biological processes that have significant implications for our overall well-being and day-to-day lives. As we continue to uncover the complex relationship between metabolism, the brain, and the leading causes of illness, the central role of mitochondria in these processes cannot be overlooked. By gaining a deeper understanding of the role of mitochondria in health and disease, we can develop novel treatment strategies that target the root cause of these conditions and pave the way for improved patient outcomes. As mitochondrial research grows, scientists, clinicians, and patients must remain open to discoveries and innovative treatment approaches.?The future of medicine lies in our ability to harness the interconnectedness of our biological systems and develop strategies that address the root causes of disease rather than simply managing symptoms.?By embracing the complexity of human health, we can move towards a more (dare I use the 'H' word?!)?Holistic, personalized, and effective approach to healthcare that ultimately improves the lives of individuals suffering from a wide range of illnesses.

Share

Leave a comment

Desiderio Pina, MD, MPH

TheMindAndBodyDoc-Physician/Neuroscientist —?@mindandbodydoc

I provide compassionate care for children (5 years & older), adolescents, adults & families struggling with nutritional, drug, & neuropsychiatric problems.

Teaching is always a privilege, and I’ve been afforded such privilege to teach at various medical schools (MD & DO), residency programs (Psychiatry, Neurology, Family Practice, and Internal Medicine), and universities; I have participated in clinical and basic science research in the past, and am currently on staff at a few hospitals, but primarily care for patients via telemedicine.

I generally talk & write about things that catch my fancy in the news and from the recent medical literature.?

These include, but are not limited to:?#wellness,?#neurosciences,?#neuropsychiatry,?#culturalpsychiatry,?#ethnobotony,?#mycology,?#mycologicalmedicine,?#digitalhealthcare,?#healthcaremanagement, and?#psychoneuroendocrineimmunology

References:

1. Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P. (2002). Molecular Biology of the Cell. Garland Science.
2. Banoth B, Cassel SL. Mitochondria in innate immune signaling. Transl Res. 2018 Dec;202:52-68. doi: 10.1016/j.trsl.2018.07.014. Epub 2018 Aug 7. PMID: 30165038; PMCID: PMC6218307.
3. Berk, M., Williams, L. J., Jacka, F. N., O'Neil, A., Pasco, J. A., Moylan, S., ... & Maes, M. (2013). So depression is an inflammatory disease, but where does the inflammation come from? BMC Medicine, 11(1), 200.
4. Cikánková T, Fi?ar Z, Bakhouche Y, ?upták M, Hroudová J. In vitro effects of antipsychotics on mitochondrial respiration. Naunyn Schmiedebergs Arch Pharmacol. 2019 Oct;392(10):1209-1223. doi: 10.1007/s00210-019-01665-8. Epub 2019 May 19. PMID: 31104106.
5. Contreras-Shannon V, Heart DL, Paredes RM, Navaira E, Catano G, Maffi SK, Walss-Bass C. Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells. PLoS One. 2013;8(3):e59012. doi: 10.1371/journal.pone.0059012. Epub 2013 Mar 20. PMID: 23527073; PMCID: PMC3604003.
6. Coskun, P., Wyrembak, J., Schriner, S. E., Chen, H. W., Marciniack, C., Laferla, F., & Wallace, D. C. (2012). A mitochondrial etiology of Alzheimer and Parkinson disease. Biochimica et Biophysica Acta (BBA) - General Subjects, 1820(5), 553-564.
7. Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nature Reviews Neuroscience, 13(10), 701-712.
8. Cunningham, C., Dunne, A., & Lopez-Rodriguez, A. B. (2018). Inflammation and the brain. In Neuroinflammation (pp. 3-17). Academic Press.
9. Dinan, T. G., & Cryan, J. F. (2017). The microbiome-gut-brain axis in health and disease. Gastroenterology Clinics of North America, 46(1), 77-89.
10. Ely, E. W., Shintani, A., Truman, B., Speroff, T., Gordon, S. M., Harrell, F. E., Jr., … & Dittus, R. S. (2004). Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA, 291(14), 1753-1762.
11. F?cking, M., Sabherwal, S., & Cagney, G. (2020). Mitochondrial dysfunction in schizophrenia: evidence from proteomic studies. Schizophrenia Bulletin, 46(4), 754-765.
12. Gardner, A., Boles, R. G., & Subramony, S. H. (2003). Mitochondrial dysfunction in psychiatric and neurological diseases: cause(s), consequence(s), and implications of antioxidant therapy. Biofactors, 17(1-4), 1-11.
13. Giulivi, C., Zhang, Y. F., Omanska-Klusek, A., Ross-Inta, C., Wong, S., Hertz-Picciotto, I., ... & Pessah, I. N. (2010). Mitochondrial dysfunction in autism. JAMA, 304(21), 2389-2396.
14. Grünewald, A., Rygiel, K. A., Hepplewhite, P. D., Morris, C. M., Picard, M., & Turnbull, D. M. (2016). Mitochondrial DNA depletion in respiratory chain-deficient Parkinson disease neurons. Annals of Neurology, 79(3), 366-378.
15. Hood, L., & Friend, S. H. (2011). Predictive, personalized, preventive, participatory (P4) cancer medicine. Nature Reviews Clinical Oncology, 8(3), 184-187.
16. Hood, L., Heath, J. R., Phelps, M. E., & Lin, B. (2004). Systems biology and new technologies enable predictive and preventative medicine. Science, 306(5696), 640-643.
17. Kann, O., Kovács, R., & Heinemann, U. (2011). Metabolic dysfunction during neuronal activation in the ex vivo hippocampus from chronic epileptic rats and humans. Brain, 134(10), 2962-2974.
18. Klinedinst, N. J., & Regenold, W. T. (2015). A mitochondrial bioenergetic basis of depression. Journal of Bioenergetics and Biomembranes, 47(1-2), 155-171.
19. Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443(7113), 787-795.
20. Maassen, J. A., 'T Hart, L. M., Van Essen, E., Heine, R. J., Nijpels, G., Jahangir Tafrechi, R. S., ... & Dekker, J. M. (2004). Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes, 53(suppl 1), S103-S109.
21. Maldonado, J. R. (2018). Delirium pathophysiology: An updated hypothesis of the etiology of acute brain failure. International Journal of Geriatric Psychiatry, 33(11), 1428-1457.
22. Manji, H., Kato, T., Di Prospero, N. A., Ness, S., Beal, M. F., Krams, M., & Chen, G. (2012). Impaired mitochondrial function in psychiatric disorders. Nature Reviews Neuroscience, 13(5), 293-307.
23. Melli, G., Taiana, M., Camozzi, F., Triolo, D., Podini, P., Quattrini, A., ... & Taroni, F. (2008). Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Experimental neurology, 214(2), 276-284.
24. Perry, V. H., Cunningham, C., & Holmes, C. (2011). Systemic infections and inflammation affect chronic neurodegeneration. Nature Reviews Immunology, 7(2), 161-167.
25. Picard, M., McEwen, B. S., Epel, E. S., & Sandi, C. (2015). An energetic view of stress: focus on mitochondria. Frontiers in neuroendocrinology, 35(1), 56-69.
26. Rebelo, A. P., Williams, S. L., & Moraes, C. T. (2011). In vivo methylation of mtDNA reveals the dynamics of protein-mtDNA interactions. Nucleic Acids Research, 39(22), 9521-9538.
27. Riley JS, Tait SW. Mitochondrial DNA in inflammation and immunity. EMBO Rep. 2020 Apr 3;21(4):e49799. doi: 10.15252/embr.201949799. Epub 2020 Mar 23. PMID: 32202065; PMCID: PMC7132203.
28. Rossignol, R., Faustin, B., Rocher, C., Malgat, M., Mazat, J. P., & Letellier, T. (2003). Mitochondrial threshold effects. Biochemical Journal, 370(3), 751-762.
29. Ryan, P. M., Patterson, E., & Cryan, J. F. (2020). Microbiota and neurodevelopmental trajectories: role of maternal and early-life nutrition. Annals of Nutrition & Metabolism, 76(Suppl. 1), 16-27.
30. Saint-Georges-Chaumet, Y., & Edeas, M. (2016). Microbiota-mitochondria inter-talk: consequence for microbiota-host interaction. Pathogens and Disease, 74(1), ftv096.Ryan, P. M., Patterson, E., & Cryan, J. F. (2020). Microbiota and neurodevelopmental trajectories: role of maternal and early-life nutrition. Annals of Nutrition & Metabolism, 76(Suppl. 1), 16-27.
31. Schon, E. A., DiMauro, S., & Hirano, M. (2012). Human mitochondrial DNA: roles of inherited and somatic mutations. Nature Reviews Genetics, 13(12), 878-890.
32. Shonkoff, J. P., Garner, A. S., Siegel, B. S., Dobbins, M. I., Earls, M. F., McGuinn, L., ... & Wood, D. L. (2012). The lifelong effects of early childhood adversity and toxic stress. Pediatrics, 129(1), e232-e246.
33. Sims, N. R., & Muyderman, H. (2010). Mitochondria, oxidative metabolism and cell death in stroke. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1802(1), 80-91.
34. Stewart, J. B., & Chinnery, P. F. (2015). The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. Nature Reviews Genetics, 16(9), 530-542.
35. Susatia F, Fernandez HH. Drug-induced parkinsonism. Curr Treat Options Neurol. 2009 May;11(3):162-9. doi: 10.1007/s11940-009-0019-3. PMID: 19364450.
36. Swerdlow, R. H. (2011). Brain aging, Alzheimer’s disease, and mitochondria. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1812(12), 1630-1639.
37. Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2010). The Alzheimer's disease mitochondrial cascade hypothesis. Journal of Alzheimer's Disease, 20(S2), S265-S279.
38. Taylor, R. W., & Turnbull, D. M. (2005). Mitochondrial DNA mutations in human disease. Nature Reviews Genetics, 6(5), 389-402.
39. Trzepacz, P. T., Saykin, A. J., Yu, M., Bhamidipati, P. K., & Alzheimer’s Disease Neuroimaging Initiative. (2017). Subcortical nuclei volumes in delirium: a confirmation study using the Alzheimer’s disease neuroimaging initiative database. Journal of Geriatric Psychiatry and Neurology, 30(1), 14-19.
40. Vucicevic L, Misirkic-Marjanovic M, Paunovic V, Kravic-Stevovic T, Martinovic T, Ciric D, Maric N, Petricevic S, Harhaji-Trajkovic L, Bumbasirevic V, Trajkovic V. Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine. Autophagy. 2014;10(12):2362-78. doi: 10.4161/15548627.2014.984270. PMID: 25551567; PMCID: PMC4502661.
41. Wallace, D. C., Fan, W., & Procaccio, V. (2010). Mitochondrial energetics and therapeutics. Annual Review of Pathology: Mechanisms of Disease, 5, 297-348.
42. Wang, X., & Green, D. R. (2012). Metabolic checkpoints in activated T cells. Nature Immunology, 13(10), 907-915.
43. Wang, W., Li, L., & Lin, W. L. (2014). The role of mitochondria in psychiatric disorders. Neurochemistry Research, 39(11), 1993-2005.
44. Weinberg SE, Sena LA, Chandel NS. Mitochondria in the regulation of innate and adaptive immunity. Immunity. 2015 Mar 17;42(3):406-17. doi: 10.1016/j.immuni.2015.02.002. PMID: 25786173; PMCID: PMC4365295.
45. Weng G, Zhou B, Liu T, Huang Z, Yang H. Sitagliptin promotes mitochondrial biogenesis in human SH-SY5Y cells by increasing the expression of PGC-1α/NRF1/TFAM. IUBMB Life. 2019 Oct;71(10):1515-1521. doi: 10.1002/iub.2076. Epub 2019 Jul 10. PMID: 31290617.
46. Witte, M. E., Geurts, J. J., de Vries, H. E., van der Valk, P., & van Horssen, J. (2010). Mitochondrial dysfunction: a potential
47. Witte, M. E., Mahad, D. J., Lassmann, H., & van Horssen, J. (2014). Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends in Molecular Medicine, 20(3), 179-187.

Desiderio Pina, MD, MPH

TheMindAndBodyDoc-Physician/Neuroscientist —?@mindandbodydoc

I provide compassionate care for children (5 years & older), adolescents, adults & families struggling with nutritional, drug, & neuropsychiatric problems.

Teaching is always a privilege, and I’ve been afforded such privilege to teach at various medical schools (MD & DO), residency programs (Psychiatry, Neurology, Family Practice, and Internal Medicine), and universities; I have participated in clinical and basic science research in the past, and am currently on staff at a few hospitals, but primarily care for patients via telemedicine.

I generally talk & write about things that catch my fancy in the news and from the recent medical literature.?

These include, but are not limited to:?#wellness,?#neurosciences,?#neuropsychiatry,?#culturalpsychiatry,?#ethnobotony,?#mycology,?#mycologicalmedicine,?#digitalhealthcare,?#healthcaremanagement, and?#psychoneuroendocrineimmunology